Aznar J A, Molina R, Montoro J M
Coagulation Disorders Unit, La Fe Hospital, Valencia, Spain.
Transfusion. 1999 Jul;39(7):748-50. doi: 10.1046/j.1537-2995.1999.39070748.x.
The effect of virus inactivation of fresh plasma with methylene blue has been studied on the factor VIII/von Willebrand factor molecular complex (FVIII/vWF), factor XIII, and fibrinogen.
FVIII function or activity, vWF activity, vWF antigen, vWF:Ag, vWF multimeric structure, fibrinogen, and factor XIII were analyzed in paired samples of control fresh plasma (untreated) and the same fresh plasma treated with methylene blue. Treated plasma was filtered (0.8-1.2 microm), mixed with a methylene blue solution (300 microg/L), and illuminated at 50,000 lux for 30 minutes on both sides.
Average loss of biologic activity of coagulation factors studied was 25 percent (FVIII function, 29%; fibrinogen, 39%; factor XIII, 16%; and vWF activity, 18%). Reduction in vWF activity was significantly lower than that in FVIII function (p<0.05), and the vWF multimeric structure did not show alterations.
Methylene blue-treated plasma and the cryoprecipitates obtained from it may be effective for replacement therapy in cases of von Willebrand disease and deficiencies of factor XIII and fibrinogen, but the clinical studies are needed to verify that possibility.
已对亚甲蓝对新鲜血浆中凝血因子Ⅷ/血管性血友病因子分子复合物（FVIII/vWF）、凝血因子ⅩⅢ和纤维蛋白原的病毒灭活效果进行了研究。
对对照新鲜血浆（未处理）和经亚甲蓝处理的同一新鲜血浆的配对样本进行FVIII功能或活性、vWF活性、vWF抗原、vWF:Ag、vWF多聚体结构、纤维蛋白原和凝血因子ⅩⅢ分析。处理后的血浆经过滤（0.8 - 1.2微米），与亚甲蓝溶液（300微克/升）混合，并在两侧以50,000勒克斯光照30分钟。
所研究凝血因子的生物活性平均损失为25%（FVIII功能，29%；纤维蛋白原，39%；凝血因子ⅩⅢ，16%；vWF活性，18%）。vWF活性的降低显著低于FVIII功能的降低（p<0.05），且vWF多聚体结构未显示改变。
亚甲蓝处理的血浆及其制备的冷沉淀可能对血管性血友病以及凝血因子ⅩⅢ和纤维蛋白原缺乏症的替代治疗有效，但需要临床研究来验证这种可能性。
